Everyone is concerned with making money on this investment.

New Post Public Reply Private Reply Replies (2) Message Board
Respert24 Hulk767 #138162
701
Everyone is concerned with making money on this investment. The difference is most everyone else doesn't trot out all the possibilities that could go wrong over and over when given no evidence those possibilities are imminent.

A lot can go wrong, a lot can go right. They've chosen to be silent until they get through the gauntlet of holds, Amarex, and NP. And we've all known that was the strategy. Nothing has changed except the fda decided to walk Cytodyn down an unexpected path, and they currently have us by the short hairs so we had to comply.

That's it. That's all the information we really have.

Nothing there to judge whether anyone on the board or within Cytodyn is competent or incompetent. Or whether the plan they've been executing is a good one or a shite one. Once the hold is lifted and we can learn more about what they've been doing throughout the hold to prepare for the future it'll be much easier to assess that. I choose to be optimistic, or at least not pessimistic, until I have information that lets me come to an informed conclusion. I choose to assume they're executing a common sense strategy that includes a partnership and launching necessary studies as soon as possible, because they've given us no indication they aren't doing that.

But hey, you are entitled to look at and talk about all possibilities, even if your assessment of their silence always reads like it's designed to scare a new investor from jumping in. So with that in mind, I decided to point out a couple you seem to have missed. I’d hate for you to not have a chance to worry publicly about every last negative possibility.

Is anyone concerned that Cyrus being so silent since returning is because he got sick and dipped into the Leronlimab backstock he had access to as the President? Then he lost both legs and his dick fell off because Leronlimab isn't as safe as maybe we thought it was? He gets demoted for his actions but they can't fire him right away because there’s no specific rule against it, then he lawyers up and both sides have to remain quiet for now? I mean, we've always been led to believe that Leronlimab is safe but if people's dicks are falling off and the company refuses to tell us about it I'm going to start worrying. Long and strong though, and I hope Leronlimab saves many lives (and dicks).

Is anyone concerned that the silence out of management might be because the fda contact Cytodyn has been meeting with all this time is possibly not a real employee of the fda at all, but rather a bunch of kids standing on each other’s shoulders and wearing a trenchcoat to pretend they’re an adult? I’m worried that this management team, who has NO EXPERIENCE in vaudeville comedy, are ill prepared to deal with this scenario. It would be a massive setback that I’m not sure we could recover from. Investor for many, many years though, and I pray Leronlimab succeeds.

Is anyone concerned that current management hasn’t told us anything about what they’ll do if they win the Powerball? Most offices I’ve ever been associated with pool their money to buy tickets when the jackpot gets large. It builds comradery, which has been MUCH needed since the NP debacle I correctly predicted. (Long and strong) But yet we hear nothing out of management about it. They can absolutely tell us if they’re buying a group ticket each week and catering in tacos on Tuesdays like any good corporate team would be doing. It doesn’t fall under SEC rules yet all we get is silence. Who’s the weirdo in the office that picks one word every sentence to say in a borderline offensive Mexican accent while eating their taco? They won’t tell us. Who on the board insists the guac has to have raw red onion in it like a psychopath? If these are the people running the company right now and they won’t speak up then I’ll be VERY worried. Show us your losing powerball tickets and receipts from Salsarita’s or I’m going to start worrying. But anyways, long as Ron Jeremy and in it to win it. Hope Leronlimab eradicates cancer for good.

Is anyone concerned about Tanya and her stewardship of the company? All we’ve gotten is silence, and since they haven’t told us exactly what they do every single day I’m starting to worry that maybe she’s a mole. I mean, look at that middle name. Durkee. Sounds foreign. Arab even. I don’t think the fda, an American institution, is going to play nicely with a company run by a possible terrorist who won’t even tell us where they stand on the Israel-Hamas war. Which they absolutely can do because it isn’t under sec rules. So why don’t they say anything? Why don’t the come out and say “hey, we don’t know much about the war going on between Israel and Hamas but we denounce all violence and support a peaceful resolution and also the rumor that Cytodyn’s board is chaired by a sleeper agent is false”. I mean, is that so hard? I’ve been invested in Cytodyn since the 1950’s and that, my friends, is hard. Why can’t the company do something so simple then? But anyways, I have Leronlimab tattooed over six hundred times on my body because I’m so long. Hope it ends all wars.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tech Job Market Surges: 86,000 Hires in August Boost

Updated Category News Views 2

Tech Job Growth Defies Corporate Layoffs Job markets in the tech world are hotter than a two-dollar pistol. Despite seeing some layoffs in tech firms, the demand for skilled tech workers is still booming. You got tech companies tightening the bolts, laying off around 14,700 folks, but here's the kicker: overall tech employment shot up with 86,000 new jobs in August....

Continue Reading
CHiQ Secures AI Award, Elevates Smart Home Living

Updated Category News Views 1

CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...

Continue Reading
IVD Study Success: Hybrid Monitoring Boosts Oversight

Updated Category News Views 1

New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...

Continue Reading
Reolink Unveils OMVI 2i Ultra at IFA 2026

Updated Category News Views 6

Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...

Continue Reading
Actinium Pharma Unveils Plans at Key Investor Conference

Updated Category News Views 2

Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
AEVEX Faces $100K+ Losses in New Investor Lawsuit

Updated Category News Views 1

When the suits start flying, folks, you know there's a mess brewing somewhere in the market. Here we are, talking about AEVEX Corp, ticker NYSE:AVEX, and they’re facing some serious heat. There's some scuttlebutt about a class action lawsuit that’s got investors clutching onto their wallets tighter than ever. If you’ve been scouring over the papers, this lawsuit is...

Continue Reading
Rho Adds Credit Card Payments to Invoices

Updated Category News Views 2

Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...

Continue Reading
CRESYN Opens Model Residence: A Peek at City Living

Updated Category News Views 3

CRESYN: Urban Elegance Hits Long Island City Who doesn't want to peek under the hood when a flashy new ride rolls into town? CRESYN's newly unveiled model residence in Long Island City is just that—an invitation to get up close and personal with what modern urban living can be. Forget the blueprints and glossy renderings. This place is the real deal, giving you that...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 2

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyst Insights on Humana's Q3 Earnings Expectations

Updated Category News Views 198

Analyst Insights on Humana's Q3 Earnings Expectations As Humana prepares for its upcoming earnings report, analysts are closely examining the expected performance metrics. The consensus among Wall Street experts is that Humana (NYSE: HUM) will report earnings of approximately $3.48 per share. This figure marks a notable decline of 55.3% compared to the same quarter last...

Continue Reading
Mastering Price Breakouts: Avoid Common Trading Pitfalls

Updated Category News Views 277

Understanding Price Breakouts in Trading Price breakouts are captivating setups in the trading world. However, traders often find themselves misled when relying solely on price movements without considering essential indicators. The reality of the market is that many breakouts are merely illusions that can deceive traders unprepared for unexpected reversals. Recognizing...

Continue Reading
Maximize Earnings: Earning $500 Monthly with Pfizer Stock

Updated Category News Views 108

Unlocking Earnings Potential with Pfizer Pfizer Inc. (NYSE: PFE) has positioned itself uniquely in the healthcare sector, and as it approaches its third-quarter earnings announcement, many investors are contemplating the opportunities its stock presents. Analysts anticipate that Pfizer will report earnings around 64 cents per share, a decrease compared to $1.06 in the...

Continue Reading
Addressing Unfair Trade Practices in the Trailer Industry

Updated Category News Views 215

The Urgent Need for Trade Protection in the Trailer Industry Undoubtedly, the American trailer industry is at a critical juncture. Recent actions by the American Trailer Manufacturers Coalition highlight the pressing need for antidumping and countervailing duties as imports of van trailers from foreign countries like China, Canada, and Mexico flood the market at unfairly...

Continue Reading
Genius Group Marks Another Milestone with Recent Buyback

Updated Category News Views 145

Genius Group Executes Share Buyback to Boost Investor Value Genius Group Limited (NYSE: GNS), a pioneering entity in the AI-driven education sector, has made headlines with its recent buyback of one million shares, a strategic move undertaken to reinforce shareholder confidence and value. This transaction occurred against the backdrop of a well-defined plan, allowing the...

Continue Reading